Literature DB >> 30771217

Radiation dose in nuclear medicine: the hybrid imaging.

Massimo Salvatori1, Alessio Rizzo2, Guido Rovera2, Luca Indovina3, Orazio Schillaci4,5.   

Abstract

Hybrid imaging procedures such as single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT) showed a rapid diffusion in recent years because of their high sensitivity, specificity, and accuracy, due to a more accurate localization and definition of scintigraphic findings. However, hybrid systems inevitably lead to an increase in patient radiation exposure because of the added CT component. Effective doses due to the radiopharmaceuticals can be estimated by multiplying the administered activities by the effective dose coefficients, while for the CT component the dose-length product can be multiplied by a conversion coefficient k. However, the effective dose value is subject to a high degree of uncertainty and must be interpreted as a broad, generic estimate of biologic risk. Although the effective dose can be used to estimate and compare the risk of radiation exposure across multiple imaging techniques, clinicians should be aware that it represents a generic evaluation of the risk derived from a given procedure to a generic model of the human body. It cannot be applied to a single individual and should not be used for epidemiologic studies or the estimation of population risks due to the inherent uncertainties and oversimplifications involved. Practical ways to reduce radiation dose to patients eligible for hybrid imaging involve adjustments to both the planning phase and throughout the execution of the study. These methods include individual justification of radiation exposure, radiopharmaceutical choice, adherence to diagnostic reference levels (DLR), patient hydration and bladder voiding, adoption of new technical devices (sensitive detectors or collimators) with new reconstruction algorithms, and implementation of appropriate CT protocols and exposure parameters.

Entities:  

Keywords:  Dose optimization; Dose reduction; Hybrid imaging; PET/CT; Radiation dose; SPECT/CT

Mesh:

Substances:

Year:  2019        PMID: 30771217     DOI: 10.1007/s11547-019-00989-y

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  6 in total

1.  Editorial from guest editors current Euratom legislation (DE 59/2013): new patient management in radiation protection.

Authors:  Giuseppe Guglielmi; Antonio Pinto; Sergio Salerno
Journal:  Radiol Med       Date:  2019-08-29       Impact factor: 3.469

Review 2.  Imaging of Uveal Melanoma-Current Standard and Methods in Development.

Authors:  Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

Review 3.  Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma.

Authors:  Danping Zhuang; Huifen Zhang; Genwen Hu; Bing Guo
Journal:  J Nanobiotechnology       Date:  2022-06-16       Impact factor: 9.429

Review 4.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

5.  [18F] Sodium Fluoride Dose Reduction Enabled by Digital Photon Counting PET/CT for Evaluation of Osteoblastic Activity.

Authors:  Maria I Menendez; Richard R Moore; Mahmoud Abdel-Rasoul; Chadwick L Wright; Soledad Fernandez; Rebecca D Jackson; Michael V Knopp
Journal:  Front Med (Lausanne)       Date:  2022-01-12

6.  On the optimization of bone SPECT/CT in terms of image quality and radiation dose.

Authors:  Monika Tulik; Piotr Tulik; Teresa Kowalska
Journal:  J Appl Clin Med Phys       Date:  2020-10-27       Impact factor: 2.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.